An Exploratory Clinical Study of Adebelimumab in Combination With Famitinib and Chemotherapy in Patients With NSCLC

NSCLC Clinical Trial

Official title:

An Exploratory Clinical Study of Adebelimumab in Combination With Famitinib and Lateral Ventricular Chemotherapy in Patients With Non-squamous NSCLC With Soft Meningeal Metastases Who Have Failed EGFR-TKI Therapy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06332300
• Other study ID #: ADBL-LC-003
• Status: Recruiting
• Phase: Phase 2
• Start date: February 1, 2024
• Est. completion date: February 1, 2026

Study information

• Verified date: January 2024
• Source: Jiangsu Province Nanjing Brain Hospital
• Contact: Shengcun Fang, PhD
• Phone: +86 13404163638
• Email: Fang1984[@]aliyun.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study was a single-arm design to explore the efficacy and safety of Adebelimumab in combination with famitinib and lateral ventricular chemotherapy in patients with floppy meningeal metastases from non-squamous NSCLC who have failed EGFR-TKI therapy, and included patients with pathologically confirmed non-squamous non-small cell lung cancer.

Description:

Despite the rapid progress of immune-combination therapy in lung cancer, immune-combination anti-vascular regimens after EGFR-TKI failure have not been explored in NSCLC LM, and further exploration of superior regimens targeting brain metastases is needed. Therefore, we plan to conduct an exploratory clinical study of adebenosumab in combination with famitinib and lateral ventricular chemotherapy in patients with non-squamous NSCLC with soft meningeal metastases who have failed EGFR-TKI therapy, with the aim of providing a more feasible and effective comprehensive treatment strategy for this group of patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 28
• Est. completion date: February 1, 2026
• Est. primary completion date: February 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Sign the informed consent form (ICF)

2. Aged 18-75 years old, male or female.

3. Histologically or cytologically confirmed EGFR mutation-positive non-squamous NSCLC (International Association for the Study of Lung Cancer (IASLC) 8th edition TNM staging criteria)

4. LM diagnosis confirmed by positive CSF cytology

5. Re-biopsy (histology or cytology or hematology) after treatment failure with at least one EGFR tyrosine kinase inhibitor (EGFR-TKI) suggesting no EGFR-sensitive mutation and possibly other treatments

6. All patients are required to have NSCLC associated with at least 1 LM site identified by the investigator that can be evaluated by MRI scanning and is amenable to repeat evaluation.

7. not required to have received systemic corticosteroids (>10mg/day prednisone or equivalent) within 2 weeks prior to enrollment

8. Expected survival = 12 weeks

9. Vital organ function within 1 week before enrollment meets the following criteria: (1) blood routine: white blood cell (WBC) =3.0×109/L; absolute neutrophil count (ANC) =1.5×109/L; platelet (PLT) =100×109/L; hemoglobin (HGB) =9.0 g/Dl (2) Liver function: aspartate transferase (AST) =2.5×ULN, alanine aminotransferase (ALT) =2.5×ULN. (3) Renal function: serum creatinine =1.5×ULN or creatinine clearance rate (creatinine) =1.5×ULN; serum bilirubin (TBIL) =2.5×ULN, alanine aminotransferase (ALT) =2.5×ULN, and in liver metastasis =5×ULN; serum bilirubin (TBIL) =1.5×ULN (except for Gilbert Syndrome =3×ULN); albumin (ALB) =30.0g/L (3) Renal function: serum creatinine =1.5×ULN or creatinine clearance rate (creatinine) =1.5×ULN. (3) Renal function: serum creatinine =1.5×ULN or creatinine clearance rate (CrCl) =50 mL/minute (using the Cockcroft/Gault formula) (4) Coagulation function: international normalized ratio (INR) =1.5; activated partial coagulation time (APCT) =1.5; activated partial coagulation time (APCT) =1.5 (4) Coagulation function: international normalized ratio (INR) =1.5, activated partial thromboplastin time (APTT) =1.5×ULN (5) Others: lipase =1.5×ULN; if lipase >1.5×ULN, the patient can be enrolled if there is no clinical or imaging evidence of pancreatitis; amylase =1.5×ULN; if amylase >1.5×ULN, the patient can be enrolled if there is no clinical or imaging evidence of pancreatitis; amylase =1.5×ULN; and amylase =1.5×ULN. or imaging evidence of pancreatitis can be enrolled. Alkaline phosphatase (ALP) = 2.5 x ULN, and in subjects with bone metastases, ALP = 5 x ULN (6) Doppler ultrasound evaluation: left ventricular ejection fraction (LVEF) = 50%

10. Female patients who are non-surgically sterilized or of childbearing potential must have a negative serum HCG test within 72 hours prior to the first dose of study medication and must not be lactating, and must agree to use appropriate contraception (e.g., intrauterine device (IUD), birth control pills, or condoms) during the study treatment period and for 3 months after the end of the study treatment period; male patients must agree to use appropriate contraceptive methods during the study treatment period and for 3 months after the end of the study treatment period. Male patients agree to use an appropriate method of contraception during and for 3 months after study treatment.

Exclusion Criteria:

1. Patients with histologic or cytopathologic diagnosis of adenosquamous carcinoma or complex SCLC.

2. Genetic tests suggesting ALK fusion, ROS1 fusion, BRAF mutation, ERBB2 (HER2) amplification/mutation, RET rearrangement, MET amplification/MET14 exon jumping mutation and NTRK fusion positivity.

3. Clinical manifestations of neurologic failure such as severe encephalopathy or treatment-related severe neurologic injury, such as chemical meningitis

4. Non-malignant neurologic diseases that would interfere with the evaluation of LM signs or symptoms

5. radiotherapy directed to the chest and whole brain completed within 4 weeks prior to enrollment (palliative radiotherapy to bone lesions completed prior to the first dose of study drug is permitted for enrollment)

6. toxicity due to prior antitumor therapy other than alopecia and malaise not recovered to CTCAE 5.0 = grade 1 prior to enrollment. Some other toxicities due to prior antitumor therapy are not expected to resolve within the expected period and have long-term persistent sequelae

7. patients with spinal cord compression that has not been cured or relieved by surgery and/or radiotherapy, or patients with previously diagnosed spinal cord compression that has been treated with compression insufficiency or total paralysis; patients with liver metastases who have received cryo- and radiofrequency ablation therapy and who still have clinically significant symptoms and abnormal hepatic function in the 4 weeks prior to enrollment

8. Presence of uncontrollable large amount of pleural effusion, pericardial effusion or ascites.

9. Presence of the following cardiac diseases: (1) cardiac function class III-IV according to NYHA cardiac function classification (2) unstable angina pectoris or electrocardiogram suggesting acute ischemia or myocardial infarction within 1 year (3) clinically significant supraventricular or ventricular arrhythmia and other conduction system abnormalities (including QTc interval greater than or equal to 450ms for men and =470ms for women) (4) clinically significant Pericardial and myocardial diseases

10. Inadequate bone marrow reserve or organ function

11. Treatment with systemic immunomodulators (including but not limited to thymidine, interferon, or interleukin-2) within 4 weeks prior to enrollment

12. Any active autoimmune disease or history of autoimmune disease; interstitial pneumonitis, drug-induced pneumonitis, radiation pneumonitis requiring steroid therapy, or active pneumonia with clinical symptoms

13. active or uncontrolled serious infection (CTCAE 5.0 = grade 2) and/or antibiotic treatment within 2 weeks prior to enrollment

14. Patients with active or undergoing treatment for tuberculosis

15. Uncontrolled hypertension (systolic blood pressure = 140 mmHg and/or diastolic blood pressure = 90 mmHg), history of hypertensive crisis or hypertensive encephalopathy

16. intracranial hemorrhage known to be unrelated to the tumor

17. imaging (CT or MRI) showing that the tumor invades large vessels or is poorly demarcated from them, or those who, in the opinion of the investigator, are predisposed to hemorrhage, with symptoms of hemoptysis or daily hemoptysis = 2.5 mL within 3 months prior to screening

18. Have had an arterial/venous thrombotic event within 24 weeks prior to enrollment, such as cerebrovascular accident (including temporary ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism.

19. Invasive surgery within 4 weeks prior to enrollment

20. Receiving medication with bleeding tendency, such as aspirin (>325 mg/day), or using full-dose oral or parenteral anticoagulants or thrombolytic agents for 2 weeks prior to enrollment.

21. Genetic predisposition to bleeding or coagulation disorders; clinically significant bleeding symptoms in the 12 weeks prior to enrollment or disorders with a clear bleeding predisposition, such as gastrointestinal bleeding, positive fecal occult blood at screening, or vasculitis.

22. History of peptic ulcer, gastrointestinal perforation, erosive esophagitis or gastritis, inflammatory bowel disease or diverticulitis, abdominal fistula, tracheo-esophageal fistula, or intra-abdominal abscess within 24 weeks prior to enrollment.

23. Urine routine suggests that urinary protein =++, and confirms that the quantitative amount of 24-hour urinary protein >1.0g

24. HBsAg positive and HBV DNA test value exceeds the upper limit of the normal reference value (1000 copies/mL or 100 IU/mL), or HCV positive (HCV RNA or HCV Ab test suggests acute and chronic infections); known history of HIV-positive disease.

25. Patients who have received a live vaccine within 12 weeks prior to enrollment

26. Known hypersensitivity to study drugs or excipients, known severe allergic reaction to any of the monoclonal antibodies

27. Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation

28. Other concurrent malignancies = 5 years prior to the first dose of study drug, with the exception of adequately treatable carcinoma in situ of the cervix, basal cell or squamous epithelial skin cancers, localized prostate cancer after radical surgery, and ductal carcinoma in situ after radical surgery

29. Known severe mental illness, alcoholism, drug addiction or drug abuse, etc.

30. Have been treated with any other experimental drug or participated in another interventional clinical study = 4 weeks prior to signing the ICF.

31. In the judgment of the investigator, the subject has other factors that may lead to the forced termination of the study, such as non-compliance with the protocol, other serious illnesses (including psychiatric illnesses) that require co-treatment, serious laboratory abnormalities, associated family or social factors, which may affect the safety of the subject, or the collection of data and samples.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• NSCLC

Intervention

Drug:
• Adebelimumab+Famitinib + FOLFIRI+Ariely
Adebelimumab in combination with famitinib and lateral ventricular chemotherapy in patients with non-squamous NSCLC with soft meningeal metastases who have failed EGFR-TKI therapy

Locations

Country	Name	City	State
China	Shengcun Fang	Nanjing	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
Jiangsu Province Nanjing Brain Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ORR	Objective remission rates for flaccid meninges	Two years of observation after enrollment
Secondary	iPFS	Intracranial progression-free survival	Two years of observation after enrollment
Secondary	iDoR	Duration of intracranial relief	Two years of observation after enrollment
Secondary	PFS	Overall progression-free survival	Two years of observation after enrollment
Secondary	OS	overall survival	Two years of observation after enrollment